Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer

November 5th 2016

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.

Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer

November 4th 2016

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

November 4th 2016

Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Yuh on Outcomes Between RT and Surgery in Prostate Cancer

November 4th 2016

Bertram Yuh, MD, an assistant clinical professor of Urologic Oncology and a urologic oncology surgeon at City of Hope, compares the outcomes with surgery and radiation treatment in patients with localized prostate cancer. Yuh shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Lau on Controversies Surrounding Prostate Cancer Screening

November 1st 2016

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Differentiating Among Surgery, RT, and Active Surveillance in Localized Prostate Cancer

November 1st 2016

Surgery and radiation therapy are standard treatment options for localized prostate cancer, but are not comparative to one another.

Dr. Zagaja on Major Benefit With Prostatectomy

November 1st 2016

Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Dr. Den on Radiation Therapy in Prostate Cancer

October 31st 2016

Robert B. Den, MD, associate professor of Radiation Oncology, Jefferson Health, discusses the use of radiation therapy as a treatment for patients with prostate cancer.

Dr. Eggener on PSA-Based Screening in Early-Stage Prostate Cancer

October 31st 2016

Scott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Active Surveillance a Valued Approach for Early Prostate Cancer

October 28th 2016

Before undergoing surgery, radiation therapy, or a systemic treatment, Clayton S. Lau, MD, advises that the active surveillance approach for some patients with early prostate cancer is likely a more effective approach—but they should be better educated on it.

Dr. Yamoah on Racial Disparities in Prostate Cancer

October 27th 2016

Kosj Yamoah, MD, a radiation oncologist at Moffit Cancer Center, discusses reasons for understanding the racial disparities in patients with prostate cancer. Yamoah shared this insight during an interview at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Neeraj Agarwal on PROSTVAC and Other Immunotherapies in Prostate Cancer

October 27th 2016

Neeraj Agarwal, MD associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses the pox viral vaccine rilimogene galvacirepvec/rilimogene glafolivec (PROSTVAC) and the future of immunotherapy in prostate cancer.

Expert Discusses Evolving Role of Chemotherapy in Hormone-Sensitive Prostate Cancer

October 27th 2016

Several recent trials have supported the use of chemotherapy in the frontline setting for patients with hormone-sensitive metastatic prostate cancer.

Intensified Radiotherapy Emerging as New Standard

October 26th 2016

Radiation therapy can be effectively delivered in more focused, intensive, and shorter-course treatment regimens that offer patients at least equivalent—and in some cases superior—outcomes in several tumor types, thus helping to mitigate challenging adverse effects of standard approaches.

Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate Cancer

October 26th 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.

FDA Updates Enzalutamide Label in mCRPC

October 21st 2016

The FDA has updated the label for enzalutamide in metastatic castration-resistant prostate cancer to include new data from the phase II TERRAIN study.

Dr. Luke Nordquist on Who Should Receive Radium-223

October 21st 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.

Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC

October 17th 2016

Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.

Dr. Daniel Eidelberg Spratt on Risk Factors in Prostate Cancer

October 17th 2016

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses challenges regarding the classification of risk groups in prostate cancer.

Dr. Twardowski on Sequencing Therapies for Patients With mCRPC

October 14th 2016

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, medical oncologist, discusses the challenge with sequencing therapies for patients with metastatic castration-resistant prostate cancer (mCRPC).